keyword
MENU ▼
Read by QxMD icon Read
search

Non-Hodgkin Lymphoma B-cell

keyword
https://www.readbyqxmd.com/read/29912583/pixantrone-novel-mode-of-action-and-clinical-readouts
#1
Giorgio Minotti, Haiyong Han, Valérie Cattan, Anton Egorov, Francesco Bertoni
Pixantrone is a first-in-class aza-anthracenedione approved as monotherapy for treatment of relapsed or refractory aggressive diffuse B-cell non-Hodgkin's lymphoma (NHL), a patient group which is notoriously difficult to treat. It has a unique chemical structure and pharmacologic properties distinguishing it from anthracyclines and anthracenediones. Areas covered: The chemical structure and mode of action of pixantrone versus doxorubicin and mitoxantrone; preclinical evidence for pixantrone's therapeutic effect and cardiac tolerability; efficacy and safety of pixantrone in clinical trials; ongoing and completed trials of pixantrone alone or as combination therapy; and the risk of cardiotoxicity of pixantrone versus doxorubicin and mitoxantrone...
June 18, 2018: Expert Review of Hematology
https://www.readbyqxmd.com/read/29910620/axicabtagene-ciloleucel-kte-c19-an-anti-cd19-car-t-therapy-for-the-treatment-of-relapsed-refractory-aggressive-b-cell-non-hodgkin-s-lymphoma
#2
REVIEW
Michael D Jain, Christina A Bachmeier, Vania H Phuoc, Julio C Chavez
Adoptive T-cell immunotherapy is a rapidly growing field and is shifting the paradigm of clinical cancer treatment. Axicabtagene ciloleucel (axi-cel) is an anti-CD19 chimeric antigen receptor T-cell therapy that was initially developed at the National Cancer Institute and has recently been commercially approved by the US Food and Drug Administration for relapsed or refractory aggressive non-Hodgkin's lymphomas including diffuse large B-cell lymphoma and its variants. The ZUMA-1 Phase I and II clinical trials formed the basis of the US Food and Drug Administration approval of this product, and we discuss the particulars of the clinical trials and the pharmacology of axi-cel...
2018: Therapeutics and Clinical Risk Management
https://www.readbyqxmd.com/read/29909914/car-t-cell-therapy-for-b-cell-lymphomas
#3
REVIEW
Julio C Chavez, Frederick L Locke
B-cell non-Hodgkin's lymphoma (NHLs)is a very heterogonous malignancy with diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL) as the most common subtypes. Standard treatment with anti-CD20 based chemoimmunotherapy is usually very effective for disease control. However a significant proportion of patients with high-risk features (double hit lymphoma, transformed lymphomas or early relapses) will become refractory to standard therapies and will have limited alternatives for cure. Adoptive therapy with chimeric antigen receptor (CAR) T-cells is a new paradigm for effective treatment of poor prognosis lymphomas...
June 2018: Best Practice & Research. Clinical Haematology
https://www.readbyqxmd.com/read/29907599/aggressive-b-cell-lymphomas-in-patients-with-myelofibrosis-receiving-jak1-2-inhibitor-therapy
#4
Edit Porpaczy, Sabrina Tripolt, Andrea Hoelbl-Kovacic, Bettina Gisslinger, Zsuzsanna Bago-Horvath, Emilio Casanova-Hevia, Emmanuelle Clappier, Thomas Decker, Sabine Fajmann, Daniela A Fux, Georg Greiner, Sinan Gueltekin, Gerwin Heller, Harald Herkner, Gregor Hoermann, Jean-Jacques Kiladjian, Thomas Kolbe, Christoph Kornauth, Maria-Theresa Krauth, Robert Kralovics, Leonhard Muellauer, Mathias Mueller, Michaela Prchal-Murphy, Eva Maria Putz, Emmanuel Raffoux, Ana-Iris Schiefer, Klaus Schmetterer, Christine Schneckenleithner, Ingrid Simonitsch-Klupp, Cathrin Skrabs, Wolfgang R Sperr, Philipp Bernhard Staber, Birgit Strobl, Peter Valent, Ulrich Jaeger, Heinz Gisslinger, Veronika Sexl
Inhibition of Janus-kinase 1/2 (JAK1/2) is a mainstay to treat myeloproliferative neoplasms (MPN). Sporadic observations reported the co-incidence of B-cell non-Hodgkin lymphomas during treatment of MPN with JAK1/2 inhibitors. We assessed 626 MPN patients including 69 with myelofibrosis receiving JAK1/2 inhibitors for lymphoma development. B-cell lymphomas evolved in 4/69 patients (5.8%) upon JAK1/2 inhibition compared to 2/557 (0.36%) with conventional treatment (16-fold increased risk). A similar 15-fold increase was observed in an independent cohort of 929 MPN patients...
June 14, 2018: Blood
https://www.readbyqxmd.com/read/29907126/nf-%C3%AE%C2%BAb-signaling-and-its-relevance-to-the-treatment-of-mantle-cell-lymphoma
#5
REVIEW
Swathi Balaji, Makhdum Ahmed, Elizabeth Lorence, Fangfang Yan, Krystle Nomie, Michael Wang
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable. The majority of patients, especially if young, achieve a progression-free survival of at least 5 years. Mantle cell lymphoma can initially be treated with an anti-CD20 antibody in combination with a chemotherapy backbone, such as VR-CAP (the anti-CD20 monoclonal antibody rituximab administered with cyclophosphamide, doxorubicin, and prednisone) or R-CHOP (the anti-CD20 monoclonal antibody rituximab administered with cyclophosphamide, doxorubicin, vincristine, and prednisone)...
June 15, 2018: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/29904021/overcoming-resistance-of-human-non-hodgkin-s-lymphoma-to-cd19-car-ctl-therapy-by-celecoxib-and-histone-deacetylase-inhibitors
#6
Antoni Xavier Torres-Collado, Ali R Jazirehi
Patients with B-cell non-Hodgkin’s lymphoma (B-NHL) who fail to respond to first-line treatment regimens or develop resistance, exhibit poor prognosis. This signifies the need to develop alternative treatment strategies. CD19-chimeric antigen receptor (CAR) T cell-redirected immunotherapy is an attractive and novel option, which has shown encouraging outcomes in phase I clinical trials of relapsed/refractory NHL. However, the underlying mechanisms of, and approaches to overcome, acquired anti-CD19CAR CD8⁺ T cells (CTL)-resistance in NHL remain elusive...
June 14, 2018: Cancers
https://www.readbyqxmd.com/read/29901111/dihydrocelastrol-exerts-potent-antitumor-activity-in-mantle-cell-lymphoma-cells-via-dual-inhibition-of-mtorc1-and-mtorc2
#7
Yongsheng Xie, Bo Li, Wenxuan Bu, Lu Gao, Yong Zhang, Xiucai Lan, Jun Hou, Zhijian Xu, Shuaikang Chang, Dandan Yu, Bingqian Xie, Yingcong Wang, Houcai Wang, Yiwen Zhang, Xiaosong Wu, Weiliang Zhu, Jumei Shi
Mantle cell lymphoma (MCL) is a distinct and highly aggressive subtype of B-cell non-Hodgkin lymphoma. Dihydrocelastrol (DHCE) is a dihydro-analog of celastrol, which is isolated from the traditional Chinese medicinal plant Tripterygium wilfordii. The present study aimed to investigate the effects of DHCE treatment on MCL cells, and to determine the mechanism underlying its potent antitumor activity in vitro and in vivo using the Cell Counting kit-8 assay, clonogenic assay, apoptosis assay, cell cycle analysis, immunofluorescence staining, western blotting and tumor xenograft models...
June 12, 2018: International Journal of Oncology
https://www.readbyqxmd.com/read/29895666/management-of-aggressive-b-cell-nhls-in-the-aya-population-an-adult-versus-pediatric-perspective
#8
Kieron Dunleavy, Thomas G Gross
The adolescents and young adult (AYA) population represent a group where mature B-cell lymphomas constitute a significant proportion of the overall malignancies that occur. Among these are aggressive B-cell non-Hodgkin lymphomas (NHLs) which are predominantly diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL) and Burkitt lymphoma (BL). For the most part, there is remarkable divide in how pediatric/adolescent patients (under the age of 18 years) with lymphoma are treated versus their young adult counterparts and molecular data are lacking, especially in pediatric and AYA series...
June 12, 2018: Blood
https://www.readbyqxmd.com/read/29893646/head-and-neck-tumors-amide-proton-transfer-mri
#9
Benjamin King Hong Law, Ann D King, Qi-Yong Ai, Darren M C Poon, Weitian Chen, Kunwar S Bhatia, Anil T Ahuja, Brigette B Ma, David Ka-Wai Yeung, Frankie Kwok Fai Mo, Yi-Xiang Wang, Jing Yuan
Purpose To evaluate the utility of amide proton transfer (APT) imaging in the characterization of head and neck tumors. Materials and Methods This retrospective study of APT imaging included 117 patients with 70 nasopharyngeal undifferentiated carcinomas (NUCs), 26 squamous cell carcinomas (SCCs), eight non-Hodgkin lymphomas (NHLs), and 13 benign salivary gland tumors (BSGTs). Normal tissues were examined in 25 patients. The APT means of malignant tumors, normal tissues, and benign tumors were calculated and compared with the Student t test and analysis of variance...
June 12, 2018: Radiology
https://www.readbyqxmd.com/read/29883922/multiple-primary-tumors-colorectal-carcinoma-and-non-hodgkin-s-lymphoma
#10
Diana A Pantoja Pachajoa, Marco Antonio Bruno, Fernando A Alvarez, Germán Viscido, Facundo Mandojana, Alejandro Doniquian
INTRODUCTION: Colorectal cancer (CRC) is the third most commonly diagnosed cancer, whereas lymphoma is the sixth leading cause of cancer death, 90% of which corresponds to non-Hodgkin's lymphoma (NHL). The association of these two primary tumors, a solid tumor with an hematological malignancy, is very uncommon. PRESENTATION OF CASE: We report the case of a 47-year-old man who presented with abdominal pain, a right upper quadrant mass and 12 kg of weight loss in 9 months...
May 30, 2018: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29881715/an-update-from-the-pediatric-proton-consortium-registry
#11
Clayton B Hess, Daniel J Indelicato, Arnold C Paulino, William F Hartsell, Christine E Hill-Kayser, Stephanie M Perkins, Anita Mahajan, Nadia N Laack, Ralph P Ermoian, Andrew L Chang, Suzanne L Wolden, Victor S Mangona, Young Kwok, John C Breneman, John P Perentesis, Sara L Gallotto, Elizabeth A Weyman, Benjamin V M Bajaj, Miranda P Lawell, Beow Y Yeap, Torunn I Yock
Background/objectives: The Pediatric Proton Consortium Registry (PPCR) was established to expedite proton outcomes research in the pediatric population requiring radiotherapy. Here, we introduce the PPCR as a resource to the oncology community and provide an overview of the data available for further study and collaboration. Design/methods: A multi-institutional registry of integrated clinical, dosimetric, radiographic, and patient-reported data for patients undergoing proton radiation therapy was conceived in May 2010...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29868471/the-role-of-macrophage-b-cell-interactions-in-the-pathophysiology-of-b-cell-lymphomas
#12
REVIEW
Lan V Pham, Elizabeth Pogue, Richard J Ford
Macrophages (MPs) are heterogeneous, multifunctional, myeloid-derived leukocytes that are part of the innate immune system, playing wide-ranging critical roles in basic biological activities, including maintenance of tissue homeostasis involving clearance of microbial pathogens. Tumor-associated MPs (TAMs) are MPs with defined specific M2 phenotypes now known to play central roles in the pathophysiology of a wide spectrum of malignant neoplasms. Also, TAMs are often intrinsic cellular components of the essential tumor microenvironment (TME)...
2018: Frontiers in Oncology
https://www.readbyqxmd.com/read/29864401/cs2164-exerts-an-antitumor-effect-against-human-non-hodgkin-s-lymphomas-in-vitro-and-in-vivo
#13
Manman Deng, Yuanfei Shi, Kai Chen, Haijun Zhao, Yan Wang, Siting Xie, Jintao Zhao, Yiming Luo, Zhihong Fang, Yaqun Fan, Bing Xu
Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders. Mounting studies have suggested an involvement of angiogenesis signaling in NHLs progression and resistance to treatment. In this study, we investigated the cytotoxicity of CS2164, a novel receptor tyrosine kinase inhibitor selectively targeting VEGFR-2 and Aurora B in NHL cells. By in vitro culture system and in vivo xenograft model, we found that CS2164 significantly inhibited cell growth and abolished clonogenicity in NHL cells in a dose- and time-dependent manner...
June 1, 2018: Experimental Cell Research
https://www.readbyqxmd.com/read/29862615/survival-in-hiv-infected-patients-with-lymphoma-according-to-the-choice-of-antiretroviral-treatment-an-observational-multicentre-study
#14
E Focà, G Cavaglià, S Rusconi, A Cascavilla, G Cenderello, A Re, S Casari, L van den Bogaart, P L Zinzani, D Caracciolo, G Di Perri, A Bonito, A Lucchini, G Cassola, P Viale, A Calcagno
OBJECTIVES: Lymphoproliferative disorders are often observed in HIV-positive patients. Combination antiretroviral treatment (cART) during antineoplastic chemotherapy is beneficial, but little is known about the clinical outcome according to different antiretroviral combinations. The aim of the study was to address this gap in current knowledge. METHODS: A retrospective study was conducted in five large Italian centres for the period from 1998 to 2015; HIV-positive patients diagnosed with lymphoma were included and demographic, clinical and therapeutic variables were recorded and associated with clinical outcomes...
June 4, 2018: HIV Medicine
https://www.readbyqxmd.com/read/29862535/rheumatoid-arthritis-and-lymphoma-incidence-pathogenesis-biology-and-outcome
#15
REVIEW
Alina Klein, Aaron Polliack, Anat Gafter-Gvili
Patients with rheumatoid arthritis (RA) have a greater risk of developing both Hodgkin lymphoma (HL) and non-HL than the general population. Non-Hodgkin lymphoma is more common than HL in these patients, and diffuse large B cell lymphoma is the most frequent subtype observed. Although the clinical course of lymphoma in RA is often aggressive, the prognosis in these cases is similar to that of lymphoma in the general population. In this review, we summarize data derived from both retrospective and prospective studies, regarding incidence, pathogenesis, and outcome of lymphomas in RA patients and outline the possible mechanisms and hypotheses linking these 2 disorders...
June 3, 2018: Hematological Oncology
https://www.readbyqxmd.com/read/29862100/primary-hepatic-burkitt-lymphoma-in-a-kidney-transplant-recipient
#16
Sophia Lionaki, Eystratios Tsakonas, Athina Androulaki, George Liapis, Panagiotis Panayiotidis, George Zavos, John N Boletis
This is a case of a renal transplant recipient who developed a primary hepatic Burkitt lymphoma a few years after kidney transplantation. The past medical history of the patient was significant for anti-HCV positivity with liver histopathology showing minimal changes of grades 0 and 1, stage 0. She received a graft from a deceased donor, with rabbit antithymocyte globulin and methyl-prednisolone, as induction therapy, and was maintained on azathioprine, cyclosporine, and low dose methyl-prednisolone with normal renal function...
2018: Case Reports in Nephrology
https://www.readbyqxmd.com/read/29860562/hyperfibrinogenemia-is-a-poor-prognostic-factor-in-diffuse-large-b-cell-lymphoma
#17
Jun-Ying Niu, Tian Tian, Hua-Yuan Zhu, Jin-Hua Liang, Wei Wu, Lei Cao, Rui-Nan Lu, Li Wang, Jian-Yong Li, Wei Xu
Diffuse large B cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphomas worldwide. Previous studies indicated that hyperfibrinogenemia was a poor predictor in various tumors. The purpose of our study was to evaluate the prognostic effect of hyperfibrinogenemia in DLBCL. Data of 228 patients, who were diagnosed with DLBCL in our hospital between May 2009 and February 2016, were analyzed retrospectively. The Kaplan-Meier method and Cox regression were performed to find prognostic factors associated with progression-free survival (PFS) and overall survival (OS)...
June 2, 2018: Annals of Hematology
https://www.readbyqxmd.com/read/29851933/the-use-of-chimeric-antigen-receptor-t-cells-in-patients-with-non-hodgkin-lymphoma
#18
Premal D Lulla, LaQuisa C Hill, Carlos A Ramos, Helen E Heslop
Resistance to conventional lines of therapy develops in approximately 20% of all patients with lymphoma. These patients have a dismal prognosis, with an expected median survival of 6.3 months. In recent years, T-cell immunotherapy has demonstrated a remarkable capacity to induce complete and durable clinical responses in patients with chemotherapy-refractory lymphoma. A major contributor to the success of immunotherapy has been the advent of genetic engineering technologies that introduce a chimeric antigen receptor (CAR) into T cells to focus their killing activity on tumor cells...
May 2018: Clinical Advances in Hematology & Oncology: H&O
https://www.readbyqxmd.com/read/29850589/small-cell-variant-of-intravascular-large-b-cell-lymphoma-highlighting-a-potentially-fatal-and-easily-missed-diagnosis
#19
Mahboubeh Rahmani, Stephanie Halene, Mina L Xu
Context: Intravascular large B-cell lymphoma (IVLBCL) is a rare non-Hodgkin B-cell lymphoma with a poor prognosis. While typically described as comprising large atypical cells restricted to the lumina of small blood vessels, it can show variability in cell size. Objective: To report the clinicopathologic features of the IVLBCL with small cell morphology and discuss the practical implications of our findings. Design: We searched our archives for all IVLBCL diagnosed in our institution for the last 25 years (1992-2017)...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29847179/epidemiological-demographic-and-clinical-data-of-chronic-viral-hepatitis-c-in-tuscany
#20
Cristina Stasi, Caterina Silvestri, Roberto Berni, Maurizia Rossana Brunetto, Anna Linda Zignego, Cristina Orsini, Stefano Milani, Liana Ricciardi, Andrea De Luca, Pierluigi Blanc, Cesira Nencioni, Donatella Aquilini, Alessandro Bartoloni, Giampaolo Bresci, Santino Marchi, Franco Filipponi, Piero Colombatto, Paolo Forte, Andrea Galli, Sauro Luchi, Silvia Chigiotti, Alessandro Nerli, Giampaolo Corti, Rodolfo Sacco, Paola Carrai, Angelo Ricchiuti, Massimo Giusti, Paolo Almi, Andrea Cozzi, Silvia Carloppi, Giacomo Laffi, Fabio Voller, Francesco Cipriani
BACKGROUND: Recent introduction of direct antiviral agents (DAAs) has completely changed the scenario regarding HCV treatment. Certain countries' economic health programs prioritise DAAs according to specific clinical features of HCV-infected patients. The aim of this study was to define epidemiological, demographic and clinical characteristics of HCV-infected patients in the Tuscany region of central Italy. METHODS: We enrolled HCV patients with chronic viral hepatitis who were referred to outpatient services of 15 hospitals in Tuscany from January 1, 2015, to December 31, 2015...
May 30, 2018: Current Medical Research and Opinion
keyword
keyword
77169
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"